The prevalence of diabetes in Central Asia has been increasing in recent years, leading to a growing demand for anti-diabetes drugs in the region.
Customer preferences: Patients in Central Asia tend to prefer oral medications over insulin injections for the treatment of diabetes. This preference is due to a combination of factors, including convenience, ease of use, and cultural attitudes towards injections.
Trends in the market: The anti-diabetes drugs market in Central Asia is experiencing a shift towards newer, more expensive medications. This trend is driven by a growing awareness of the importance of managing diabetes effectively, as well as an increasing willingness among patients to pay for higher-quality drugs. Additionally, there is a growing trend towards the use of combination therapies, which involve the use of multiple drugs to control blood sugar levels.
Local special circumstances: One of the key challenges facing the anti-diabetes drugs market in Central Asia is the lack of access to healthcare in many parts of the region. This has led to a high prevalence of undiagnosed diabetes, as well as a lack of access to medication for those who have been diagnosed. Additionally, there are significant disparities in healthcare access and quality between urban and rural areas, which can make it difficult for patients in remote regions to receive the care they need.
Underlying macroeconomic factors: The economic development of Central Asia is a key driver of the anti-diabetes drugs market in the region. As incomes rise and lifestyles change, the prevalence of diabetes is expected to continue to increase. Additionally, the growing availability of healthcare services and the increasing adoption of Western healthcare practices are likely to drive demand for anti-diabetes drugs in the coming years. However, the high cost of these medications may limit their accessibility to certain segments of the population, particularly those in rural areas or with lower incomes.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
